BioSpace News Archive

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that David Fox has been appointed to Gamida Cell’s board of directors as an independent member. Mr. Fox brings significant leadership, company-building and business development experience to Gamida Cell’s board of directors as the company advances its clinical development candid

Initiation of pivotal PURSUIT trial is targeted for Q4 2020 following pending results from Companys SUI feasibility study, which is evaluating a new sham treatment tip PURSUIT clearance and pending results from the SUI feasibility study are significant milestones in Companys pursuit of a stress urinary incontinence indication in the U.S.

Nucleai (www.Nucleaimd.com), an Israeli start-up providing an artificial intelligence-powered precision oncology platform for research and treatment decisions and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, manufacturing and digital health investment, announced today the Series-A initial closing of $6.5M

The Prostate Cancer Foundation (PCF) has collaborated with a consortium of 41 leading patient advocacy organizations, professional societies and industry partners to publish a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group company, today announced the companies have entered a multi-year agreement for current Good Manufacturing Practice (cGMP)-compliant cleanroom space for Editas Medicine in Azzur’s Waltham site. Editas Medicine will utilize the space and Azzur’s services to execute pre-clinical and early-phase clinic

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with the University of Oxford for its large scale clinical trial focused on COVID-19 preventative treatments.

Today ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH. The grant was conferred for the development of a long acting parathyroid hormone – PTH(1-34) – that can be administered once-weekly for treatment of hypo-parathyroidism. To achieve this, ProLynx will employ its platform half-life extension technology using its hydrogel microsphere carriers. The approved PTH replacement therapy is PTH(1-84), o

Pacgen Life Science Corporation (“Pacgen” or the “Company”) (TSX-V: PBS) announced today that it has reached a definitive agreement pursuant to which General Biologicals Corporation (“GBC”), a Taiwan-based diagnostic and pharmaceutical company, will acquire the issued and outstanding shares of Pacgen in an all cash transaction. The proposed transaction will be implemented by way of a court-approved plan of arrangement (the “Arra

Vxtra Health, a new entry in the burgeoning health insurtech market announced today the appointment of Tim Attebery as chairman of the board. Recognized as one of the most innovative healthcare executives in America, Attebery joins the

Avoid fluoride during pregnancy and infancy to protect babies’ brains, caution fluoride researchers in the Journal of Pediatrics (“Current Best Evidence,” July 2020), reports the New York State Coalition Opposed to Fluoridation, Inc. (NYSCOF).